HOME >> BIOLOGY >> NEWS
Improved NIST SRM aids lead poisoning detection

od obtained from goats. The red blood cell system of an adult goat is much closer to that of a human, making it a better model for assessing proficiency for erythrocyte protoporphyrin, a biomarker of lead exposure. NISTs partner in developing 955c, the New York State Department of Healths Wadsworth Center Lead Poisoning Laboratory, dosed adult goats with lead acetate to produce blood pools containing lead physiologically bound to red blood cells.* The new SRM provides a better match than its predecessor to the blood samples clinicians analyze. The lead concentrations were determined by NIST using highly specialized methodology that resulted in high accuracy and low measurement uncertainty.

The changing goal line for blood lead concentration makes SRM 955c especially useful to laboratories. The lowest lead concentration level in the previous standard was 4 micrograms per deciliter or 40 parts per billion. In contrast, the lowest lead concentration level of SRM 955c is 0.4 microgram per deciliter or four parts per billion, the level of lead in an undosed animal. It is intended to represent the natural level of lead in an unexposed human population (although it is not yet known if any lead is naturally present in human blood). The lowest concentration in the SRM is 25 times lower than the DHHS 2010 goal, and will enable the development of next generation clinical methods that will be needed to accurately measure blood lead levels in children as progress is made toward eliminating lead exposure.

In addition to lead, levels two through four of SRM 955c contain added amounts of arsenic, cadmium, mercury, methylmercury and ethylmercury to facilitate future efforts to develop clinical methods to measure these toxins in human blood. At present, NIST provides information values only for the concentrations of cadmium and total mercury (including methylmercury and ethylmercury.) As values become available for arsenic, methylmercury and ethylmercury, the cert
'"/>

Contact: John Blair
john.blair@nist.gov
301-975-4261
National Institute of Standards and Technology (NIST)
3-Aug-2007


Page: 1 2 3

Related biology news :

1. Improved predictions of warming-induced extinctions sought
2. Improved imaging for identifying breast cancer in overweight women
3. Improved speech without vocal cords
4. Improved blood safety measures from Pall can increase platelet availability
5. Improved statistical tools reveal many linked loci
6. Improved process of drying lumber may save millions
7. Improved cancer treatments aim of new biology research program
8. Improved recipe for magnetic brain stimulation
9. Improved molecular switch could serve as sensor, medical tool
10. Leading the fight against food poisoning
11. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improved NIST SRM aids lead poisoning detection

(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
Cached News: